Comparison of the subchronic antidiabetic effects of DPP IV - resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice

Journal of Peptide Science

Volumn 13, Issue 6, 2007, Pages 400-405

  Irwin, Nigel ^a   McClean, Paula L ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Analogue; Dipeptidylpeptidase IV (DPP IV); Glucagon like peptide 1 (GLP 1); Glucose homeostasis; Glucose dependent insulinotropic polypeptide (GIP); Obese diabetic (ob ob) mouse

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; INSULIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL CLONING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENZYME DEGRADATION; EVIDENCE BASED MEDICINE; EXPERIMENTAL DIABETES MELLITUS; FOOD INTAKE; GASTROINTESTINAL TRACT; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HORMONE RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN SENSITIVITY; MONOTHERAPY; MOUSE; NONHUMAN; OBESITY; PANCREAS CELL; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MICE; OBESITY;

MUS;

EID: 34250221536     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.861     Document Type: Article

References (33)

1. Creutzfeldt W. The entero-insular axis in type 2 diabetes-incretins as therapeutic agents. Exp. Clin. Endocrinol. Diab. 2001; 109: 288-303.
2. Trumper A, Trumper K, Trusheim H, Arnold R, Goke B, Horsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol. Endocrinol. 2001; 15: 1559-1570.
3. Trumper A, Trumper K, Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J. Endocrinol. 2002; 174: 233-246.
4. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002; 51: 1443-1452.
5. Gault VA, O'Harte FPM, Flatt PR. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? Neuropeptides 2003; 37: 253-263.
6. Meier JJ, Gallwitz B, Nauck MA. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus. BioDrugs 2003; 17: 93-102.
7. Ahren B. Gut peptides and type 2 diabetes mellitus treatment. Curr. Diab. Rep. 2003; 3: 365-372.
8. Drucker DJ. The role of gut hormones in glucose homeostasis. J. Clin. Invest. 2007; 117: 24-32.
9. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm. Metah. Res. 2004; 36: 761-765.
10. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Reg. Pept. 1999; 85: 9-24.
11. 9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39). Metabolism 2004; 53: 252-259.
12. Gault VA, Parker JC, Harriott P, Flatt PR, O'Harte FPM. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide (GIP), GIP(3-42), is a GIP receptor antagonist in vivo. J. Endocrinol. 2002; 175: 525-553.
13. Green BD, Gault VA, O'Harte FP, Flatt PR. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr. Pharm. Des. 2004; 10: 2651-3662.
14. Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab. Vasc. Dis. Res. 2006; 3: 159-165.
15. Green BD, Gault VA, Mooney MH, Irwin N, Bailey CJ, Harriott P, Greer B, Flatt PR, O'Harte FPM. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. J. Mol. Endocrinol. 2003; 31: 529-540.
16. O'Harte FPM, Gault VA, Parker JC, Harriott P, Mooney MH, Bailey CJ, Flatt PR. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of glucose-dependent insulinotropic polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia 2002; 45: 1281-1291.
17. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide, and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol. Metab. 1993; 76: 912-917.
18. Miki T, Minami K, Shinozaki H, Matsumura K, Saraya A, Ikeda H, Yamada Y, Holst JJ, Seino S. Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. Diabetes 2005; 54: 1056-1063.
19. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J. Biol. Chem. 1986; 261: 11880-11889.
20. Inagaki N, Seino Y, Takeda J, Yano H, Yamada Y, Bell GI, Eddy RL, Fukushima Y, Byers MG, Shows TB. Gastric inhibitory polypeptide: structure and chromosomal localization of the human gene. Mol. Endocrinol. 1989; 3: 1014-1021.
21. Moens K, Heimberg H, Flamez D, Huypens P, Quartier E, Ling Z, Pipeleers D, Gremlich S, Thorens B, Schuit F. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 1996; 45: 257-261.
22. Bailey CJ, Flatt PR, Atkins TW. Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ ob mice. Int. J. Obes. 1982; 6: 11-21.
23. 13)GIP. Cell Biol. Int. 2003; 27: 41-46.
24. McClenaghan NH, Barnett CR, Ah-Sing E, Abdel-Wahab YH, O'Harte FP, Yoon TW, Swanston-Flatt SK, Flatt PR. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 1996; 45: 1132-1140.
25. Stevens JF. Determination of glucose by an automatic analyser. Clin. Chem. Acta. 1971; 32: 199-201.
26. Flatt PR, Bailey CJ. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 1981; 20: 573-577.
27. Burington RS. Handbook of Mathematical Tables and Formulae. McGraw-Hill: New York, 1973.
28. Baggio LL, Drucker DJ. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu. Rev. Med. 2006; 57: 265-281.
29. Woods SC, West DB, Stein LJ, McKay LD, Lotter EC, Porte SG, Kenney NJ, Porte D Jr. Peptides and the control of meal size. Diabetologia 1981; 20: S305-S313.
30. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004; 127: 546-558.
31. 8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. J. Pharmacol. Exp. Ther. 2006; 318: 914-921.
32. Delmeire D, Flamez D, Moens K, Hinke SA, Van Schravendijk C, Pipeleers D, Schuit F. Prior in vitro exposure to GLP-1 with or without GIP can influence the subsequent beta cell responsiveness. Biochem. Pharmacol. 2004l 68: 33-39.
33. Irwin N, McClean PL, Cassidy RC, O'Harte FPM, Green BD, Gault VA, Harriott P, Flatt PR. Comparison of the antidiabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: Studies with DPP IV resistant N-AcGIP and exendin(1-39)amide. Diab. Metab. Res. Rev. 2007 (in press).